SARASOTA, Fla., Jan. 29, 2026 (GLOBE NEWSWIRE) -- INVO Fertility Inc. (“INVO” or the “Company”) (NASDAQ: IVF), a healthcare company focused on the fertility market, today announced it has entered into a warrant inducement agreement with an investor (“Investor”) for the immediate exercise of certain outstanding warrants that the Company issued on December 3, 2025 (the “December 2025 Warrants”). Pursuant to a warrant inducement agreement, the Investor has agreed to a reduced exercise price of the outstanding ...

Company Overview - INVO Fertility, Inc. is a healthcare fertility company focused on establishing, acquiring, and operating fertility clinics and related technologies [3] - The company operates two INVO Centers and one IVF clinic in the United States, and it sells the INVOcell medical device to third-party fertility clinics [3] - INVOcell is a proprietary medical device that allows fertilization and early embryo development to occur in vivo within the woman's body, offering a more intimate and affordable experience compared to traditional ART treatments [3] Upcoming Event - INVO Fertility will participate in a webcast fireside chat at the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026, at 3:00 p.m. ET [1][2] - The webcast can be accessed through the conference home page or directly via provided links, with a replay available afterward [2]

Core Viewpoint - INVO Fertility, Inc. has announced a realignment of its executive leadership team to better support its growth strategy focused on the establishment and acquisition of fertility clinics and related businesses [1][3]. Leadership Changes - Terah Krigsvold has been appointed as the new Chief Financial Officer (CFO), replacing Andrea Goren, who will now serve as Chief Business Officer and CEO of INVO Centers LLC, a subsidiary focused on fertility clinics [2][3]. - The leadership changes are intended to enhance the company's ability to execute its growth plan and achieve profitability [3]. Company Strategy - INVO Fertility is dedicated to expanding access to assisted reproductive technology (ART) and focuses on building, acquiring, and operating fertility clinics, including INVO Centers that utilize the INVOcell medical device [4]. - The company currently operates two INVO Centers and one IVF clinic in the United States and is involved in the sale and distribution of the INVOcell device to third-party clinics [4]. Product Offering - The INVOcell device allows fertilization and early embryo development to occur in vivo within the woman's body, providing a more intimate and affordable experience compared to traditional ART treatments [4]. - The IVC procedure enabled by INVOcell is believed to deliver comparable results to traditional IVF at a significantly lower cost and is more effective than intrauterine insemination [4].

Core Viewpoint - INVO Fertility, Inc. has signed a definitive purchase agreement to acquire Family Beginnings, P.C., marking a significant step in its strategy to expand its fertility care centers across the United States [1][2]. Group 1: Acquisition Details - The purchase agreement follows the announcement made on November 27, 2025, regarding the intent to acquire Family Beginnings [2]. - Family Beginnings generated approximately $1.2 million in revenue and $0.2 million in net income for the 12-month period ending September 30, 2025 [2]. - The total purchase price for the acquisition is $750,000, with $350,000 to be paid in cash at closing and $400,000 in preferred stock [4]. Group 2: Strategic Importance - The acquisition aligns with INVO's mission to enhance access to advanced fertility care and expand its operational footprint [3]. - Family Beginnings is recognized for its strong clinical reputation and offers a comprehensive range of reproductive services, including IVF and fertility preservation [3]. Group 3: Leadership and Integration - Dr. James Donahue will continue to lead Family Beginnings under a three-year agreement following the acquisition [4]. - The integration of Family Beginnings into INVO's operations is anticipated to build upon the existing foundation and further grow the practice in the local market [3].

Core Viewpoint - INVO Fertility, Inc. has announced a private placement offering to raise approximately $4.0 million through the sale of common stock and warrants, aimed at expanding its operations in the fertility market [1][2]. Group 1: Offering Details - The company will sell 2,366,864 shares of common stock and warrants to purchase up to 4,733,728 additional shares, with a combined effective offering price of $1.69 per share [1]. - The warrants will have an exercise price of $1.69 per share, exercisable upon shareholder approval, and will expire five years from the date of such approval [1]. - The offering is expected to close on or about December 3, 2025, pending customary closing conditions [2]. Group 2: Financial Implications - Gross proceeds from the offering are estimated to be approximately $4.0 million before deducting fees and expenses related to the placement [2]. - Maxim Group LLC is acting as the sole placement agent for this offering [2]. Group 3: Company Overview - INVO Fertility is focused on expanding assisted reproductive technology (ART) care, operating fertility clinics, and distributing its proprietary INVOcell technology [5]. - The company operates two INVO Centers and one IVF clinic in the United States, offering the intravaginal culture (IVC) procedure, which is designed to provide a more natural and cost-effective alternative to traditional IVF [5]. - The INVOcell device allows fertilization and early embryo development to occur in vivo, potentially delivering comparable results to traditional methods at a lower cost [5].

Core Insights - INVO Fertility, Inc. is set to acquire Family Beginnings, P.C., enhancing its national expansion strategy and clinical capabilities in the Midwest [1][4] - This acquisition follows INVO's previous purchase of Wisconsin Fertility Institute in 2023, indicating a strategic initiative to build a nationwide network of fertility centers [1][4] Company Overview - INVO Fertility focuses on establishing, acquiring, and operating fertility clinics and related technologies, with a commitment to expanding access to assisted reproductive technology (ART) [8] - The company operates two INVO Centers and one IVF clinic in the U.S., and is engaged in the sale and distribution of its proprietary INVOcell medical device [8] Acquisition Details - Family Beginnings is recognized for its high standards of care and has served thousands of patients in Indiana and surrounding states, offering a full suite of reproductive services [2][3] - The acquisition aims to introduce expanded treatment options, invest in clinic infrastructure, and integrate digital patient engagement tools [6] - The transaction is subject to customary due diligence and negotiation of definitive purchase agreements [4][7] Strategic Goals - The acquisition aligns with INVO's mission to make fertility care more accessible and patient-centered, leveraging strategic acquisitions to accelerate growth [4] - INVO plans to enhance the Family Beginnings clinic by broadening offerings and ensuring high-quality care for more patients [3][6]

Core Viewpoint - INVO Fertility, Inc. will implement a 1-for-8 reverse stock split effective November 28, 2025, to enhance its stock price and maintain compliance with Nasdaq listing requirements [1][2]. Company Overview - INVO Fertility is a healthcare services company focused on the fertility market, particularly in expanding assisted reproductive technology (ART) care [3]. - The company's strategy includes building, acquiring, and operating fertility clinics, specifically "INVO Centers" that offer the intravaginal culture (IVC) procedure using the proprietary INVOcell medical device [3]. - INVO Fertility currently operates two INVO Centers and one IVF clinic in the United States and distributes the INVOcell technology to third-party fertility clinics [3]. - The IVC procedure is designed to provide a more natural, intimate, and cost-effective alternative to traditional IVF, with comparable results at a lower cost [3].

Core Insights - INVO Fertility reported a strong financial performance in Q3 2025, with total revenue increasing by 23% year-over-year to $1,757,094, driven by higher patient volumes and enhanced marketing efforts [5][4] - The company achieved 18% organic growth across its clinics, attributed to increased patient flow and expanded telehealth capabilities [5][4] - The recent policy updates allowing employers to offer standalone infertility benefits are expected to further enhance access to IVF treatments, contributing to industry growth [5][4] Financial Highlights - Total revenue for Q3 2025 was $1,757,094, up from $1,433,151 in Q3 2024, marking a 23% increase [5] - Consolidated clinic revenue increased by 21% to $1,722,223 compared to $1,418,011 in the previous year [5] - The net loss for the quarter was $(2.6) million, compared to $(1.6) million in Q3 2024 [5] Operational and Strategic Highlights - The company is focused on strengthening organic performance and pursuing acquisition opportunities, with a pipeline of target clinics for potential acquisition [4] - INVOcell device revenue grew by 130% year-over-year, reflecting successful expansion initiatives and improved pricing strategies [5][4] - Operational efficiencies are being pursued through partnerships, such as with Heidi Health for AI-powered solutions [5][6] Management Commentary - The CEO emphasized the importance of organic growth and acquisition strategies in driving the company's mission to enhance patient access to fertility services [4] - The company is committed to operational efficiency to achieve profitability while expanding its services [6]

Core Insights - INVO Fertility has announced a strategic partnership with Heidi Health to integrate an AI-powered scribe platform at its Wisconsin Fertility Institute, aimed at enhancing patient care and reducing administrative burdens for clinicians [1][3]. Company Overview - INVO Fertility is a healthcare services company focused on expanding access to assisted reproductive technology (ART) through the establishment, acquisition, and operation of fertility clinics [5]. - The company operates two INVO Centers in the U.S. and one IVF clinic, and it is engaged in the sale and distribution of its proprietary INVOcell technology, which allows fertilization and early embryo development to occur in vivo [5]. Technology Integration - The AI-powered tool from Heidi Health automates clinical documentation, allowing clinicians to spend less time on administrative tasks, thus reducing burnout and improving patient interaction [2][3]. - The integration of the AI scribe is expected to automate over two hours of daily administrative work for clinicians, significantly decreasing manual note-taking by up to 80% [3]. Patient Experience Enhancement - The partnership aims to elevate the patient experience at the Wisconsin clinic, ensuring that individuals feel supported throughout their treatment journey [4]. - The technology will enable specialists to focus more on patient care, building trust, and personalizing treatment plans [3][4].

Core Insights - INVO Fertility, Inc. will participate in the Lytham Partners Fall 2025 Investor Conference, hosting a webcast presentation and one-on-one meetings with investors on September 30, 2025 [1][2][3] Company Overview - INVO Fertility is a healthcare services company focused on expanding access to assisted reproductive technology (ART) through the establishment, acquisition, and operation of fertility clinics [4] - The company's primary strategy includes building and operating "INVO Centers" that offer the intravaginal culture (IVC) procedure using the proprietary INVOcell medical device, which allows fertilization and early embryo development to occur in vivo within the woman's body [4] - INVO Fertility currently operates two INVO Centers and one IVF clinic in the United States, and it also sells and distributes the INVOcell device to third-party fertility clinics [4] - The IVC procedure is designed to provide a more connected, intimate, and affordable experience compared to traditional ART treatments, potentially delivering comparable results at a lower cost than traditional IVF [4]